Parkinson's Disease Virtual Issue

Parkinson's Disease Virtual Issue

Welcome to the Neuroscience Virtual Issue on Parkinson’s Disease

Defined by degeneration of the dopaminergic projections in the nigrostriatal pathway and characterized largely by impaired motor function, Parkinson’s disease (PD) is the second most common neurodegenerative disorder among those over the age of 60 and it is currently estimated that over 6 million people worldwide suffer from this disease. As this number is expected to increase rapidly over the next two decades and current therapies have proven to be only partially beneficial for just a portion of disease symptoms, the emphasis on the need for better treatment and a deeper understanding of PD cannot be overstated.

While research efforts in this field have traditionally focused on the most outwardly noticeable symptoms of the disease, the research and medical community have become increasingly cognizant of the urgency to elucidate the mechanisms behind non-motor related aspects of the disease such as disorders of balance, mood, and cognition. In recent years, a variety of scientific and technological developments have supported the growth of research studies aimed at addressing these issues and significant strides have been made in translational research as well. Advances in brain imaging, stem cell technology, gene and pharmacological therapy have helped scientists to better model and study PD in addition to developing novel therapeutic approaches targeting earlier stages of the disease, at times presymptomatically, with the hopes of preventing or delaying the onset disease symptoms.

Two years ago, April was declared as Parkinson’s Awareness Month. In honor of this occasion, we present this virtual issue on Parkinson’s disease, comprised of research articles published in recent years from several of our high-impact neuroscience journals. Each article highlights different advances that have deepened our understanding of both the disease and potential new treatments while also framing new questions for us to consider as we look to the future. We are pleased to contribute to the goals and aims of Parkinson’s Awareness Month by highlighting and reflecting upon these studies.

Developmental Neurobiology

Synaptic vesicle trafficking and Parkinson's disease
Giovanni Esposito, Fernandes Ana Clara and Patrik Verstreken

Genes, Brain and Behavior

Mice lacking the Parkinson's related GPR37/PAEL receptor show non-motor behavioral phenotypes: age and gender effect
S. Mandillo, E. Golini, D. Marazziti, C. Di Pietro, R. Matteoni and. P. Tocchini-Valentini


NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration
Liya Qin,Yuxin Liu, Jau-Shyong Hong and Fulton T. Crews

PINK1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced AKT and increased p38 MAPK activation, and downregulation of EGFR
Insup Choi, Jun Kim, Hey-Kyeong Jeong, Beomsue Kim, Ilo Jou, Sang Myun Park, Linan Chen, Un-Jung Kang, Xiaoxi Zhuang and Eun-hye Joe


Regional vulnerability of hippocampal subfields and memory deficits in Parkinson's disease
Joana B. Pereira, Carme Junqué, David Bartrés-Faz, Blanca Ramírez-Ruiz, Maria-Jose Marti and Eduardo Tolosa

Human Brain Mapping

Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease
Ji Hyun Ko, Francesca Antonelli, Oury Monchi, Nicola Ray, Pablo Rusjan, Sylvain Houle, Anthony E. Lang, Leigh Christopher and Antonio P. Strafella

Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness
Joana Braga Pereira, Naroa Ibarretxe-Bilbao, Maria-Jose Marti, Yaroslau Compta, Carme Junqué , Nuria Bargallo and Eduardo Tolosa

Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment
Carlo Tessa, Claudio Lucetti, Marco Giannelli, Stefano Diciotti, Michele Poletti, Sabrina Danti, Filippo Baldacci, Claudio Vignali, Ubaldo Bonuccelli, Mario Mascalchi and Nicola Toschi

Journal of Comparative Neurology

Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?
Philip C. Buttery and Roger A. Barker

Primate adult brain cell autotransplantation produces behavioral and biological recovery in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian St. Kitts monkeys
Jocelyne Bloch, Jean-François Brunet, Caleb R.S. McEntire and D. Eugene Redmond

Fibroblast growth factor 2 regulates adequate nigrostriatal pathway formation in mice
Olga Baron, Andreas Ratzka and Claudia Grothe

Journal of Neuroscience Research

Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease
Sudhakar R. Subramaniam and Elizabeth M. Ellis


Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease
Serge Maia, Nicolas Arlicot, Emilie Vierron, Sylvie Bodard, Jackie Vergote, Denis Guilloteau and Sylvie Chalon

Electrophysiological and behavioral effects of group III metabotropic glutamate receptors on pallidal neurons in normal and parkinsonian rats
Xiang-Rong Sun, Lei Chen, Wen-Fang Chen, Yan Xue and Wing-Ho Yung

View all products in Neuroscience

View Current Protocols in Neuroscience